<b>Kensey Nash </B>(Exton, Pennsylvania) last month rearranged some of its interventional priorities, reporting that it will leave the embolic protection sector, primarily in carotid stenting. Citing a slow-growing market with extremely high costs, the company said it will discontinue its TriActiv System platforms and the ProGuard system.